Chinook Therapeutics Announces Proposed Public Offering of Common Stock
November 08, 2021 16:01 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 08, 2021 08:00 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021
November 04, 2021 13:05 ET
|
Chinook Therapeutics, Inc.
BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301 demonstrated >50%...
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2021
October 15, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on the...
Chinook Therapeutics to Present at Upcoming Investor Conferences
September 20, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at Upcoming Investor Conferences
September 02, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021
July 12, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 07, 2021 16:05 ET
|
Chinook Therapeutics, Inc.
SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief Scientific Officer
June 09, 2021 08:15 ET
|
Chinook Therapeutics, Inc.
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...